New applications of gemcitabine and future directions in the management of pancreatic cancer
New applications of gemcitabine and future directions in the management of pancreatic cancer
复制标题
DOI：
10.1002/cncr.10753
复制
发表时间：
2002-08-15
期刊：
影响因子：
6.2
通讯作者：
Abbruzzese, JL
中科院分区：
文献类型：
--
作者：
Abbruzzese, JL
据报道，吉西他滨是治疗胰腺癌的活性药物。最近的应用包括在晚期胰腺癌患者中使用固定剂量方案，该方案基于观察到脱氧胞苷激酶在标准输注达到的血浆吉西他滨浓度下饱和，从而限制细胞内吉西他滨三磷酸的积累。在一项 11 期研究中，该方案与晚期疾病患者中通常观察到的生存率相关。吉西他滨还被评估为局部晚期癌症的放射增敏剂，尽管毒性显着，但观察到了客观反应，包括肿瘤反应，这使得治愈性切除成为可能。胰腺癌治疗的未来方向包括基于对分子事件在致癌作用中作用的不断加深的理解，开发针对信号转导途径和核转录因子的药物。 (C) 2002 年美国癌症协会。
Gemcitabine has been reported to be an active agent in pancreatic cancer. Recent applications have included the use of a fixed-dose rate regimen in patients with advanced pancreatic cancer based on the observation that deoxycytidine kinase is saturated at the plasma gemcitabine concentrations achieved with standard infusion, thereby limiting the accumulation of intracellular gemcitabine triphosphate. In a Phase 11 study, this regimen was associated with survival rates better than those typically observed in patients with advanced disease. Gemcitabine also has been assessed as a radiosensitizer in locally advanced cancer and although toxicity was significant, objective responses were observed and included tumor response, which permitted curative resection. Future directions in therapy for pancreatic cancer include the development of agents targeting signal transduction pathways and nuclear transcription factors based on the continually improving understanding of the role of molecular events in carcinogenesis. (C) 2002 American Cancer Society.